Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized epinephrine for prevention of extubation failure in neonates
IRCT20201222049802N5Phase 3Completed
- Sponsor
- Zanjan University of Medical Sciences
- Start
- May 2025
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in respiratory failure comparing Nebulized epinephrine with Placebo nebulized normal saline (2 arms). Primary endpoints: Extubation success at 24 hours, Extubation success at 48 hours and 2 more. Started May 2025; status: completed.
02
Drugs
epinephrine
03
Conditions
respiratory failure
Beyond the preview
Go deeper on IRCT20201222049802N5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201222049802N5.